{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:05:26Z","timestamp":1770185126116,"version":"3.49.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1681\/asn.0000000877","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T16:02:19Z","timestamp":1756828939000},"page":"390-393","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes"],"prefix":"10.1681","volume":"37","author":[{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"},{"name":"Inserm, Centre d'Investigations Cliniques-Plurith\u00e9matique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Universit\u00e9 de Lorraine, Nancy, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-3941","authenticated-orcid":false,"given":"Lu\u00eds","family":"Mendon\u00e7a","sequence":"additional","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1120-5461","authenticated-orcid":false,"given":"Pedro","family":"Marques","sequence":"additional","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-8255","authenticated-orcid":false,"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[{"name":"RISE-Health, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm, Centre d'Investigations Cliniques-Plurith\u00e9matique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Universit\u00e9 de Lorraine, Nancy, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas"}]}],"member":"276","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"12","key":"B1-20260203","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med."},{"issue":"22","key":"B2-20260203","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jacc.2024.08.034","article-title":"Why has it been challenging to modify kidney disease progression in patients with heart failure?","volume":"84","author":"Vaduganathan","year":"2024","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"B3-20260203","doi-asserted-by":"crossref","first-page":"102514","DOI":"10.1016\/j.jchf.2025.102514","article-title":"MRAs, SGLT2 inhibitors and kidney outcomes in CKD and HF: differences in diseases, drugs, or both?","volume":"13","author":"Mendon\u00e7a","year":"2025","journal-title":"JACC Heart Fail."},{"issue":"7","key":"B4-20260203","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.3649","article-title":"Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"27","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail."},{"issue":"23","key":"B5-20260203","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"New Engl J Med."},{"issue":"24","key":"B6-20260203","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"New Engl J Med."},{"issue":"4","key":"B7-20260203","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.amjcard.2018.11.022","article-title":"Comparison of outcomes in patients with diabetes mellitus treated with versus without insulin + heart failure with preserved left ventricular ejection fraction (from the TOPCAT study)","volume":"123","author":"Huynh","year":"2019","journal-title":"Am J Cardiol."},{"issue":"5","key":"B8-20260203","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ejhf.3569","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis","volume":"27","author":"Mentz","year":"2025","journal-title":"Eur J Heart Fail."},{"issue":"4","key":"B9-20260203","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ndt\/gfad215","article-title":"Tubular toxicity of proteinuria and the progression of chronic kidney disease","volume":"39","author":"Makhammajanov","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B10-20260203","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.kint.2018.08.024","article-title":"Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx","volume":"95","author":"Butler","year":"2019","journal-title":"Kidney Int."},{"issue":"5","key":"B11-20260203","doi-asserted-by":"crossref","first-page":"e154164","DOI":"10.1172\/jci.insight.154164","article-title":"Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx","volume":"8","author":"Crompton","year":"2023","journal-title":"JCI Insight."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1681\/ASN.0000000877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:03:53Z","timestamp":1770138233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1681\/ASN.0000000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000000877","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}